Matching articles for "uveal melanoma"
Issue 1705 · June 24, 2024
Tebentafusp (Kimmtrak) for Uveal Melanoma (online only)

The FDA has approved tebentafusp-tebn ( Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic…

Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e107-8 doi:10.58347/tml.2024.1705f
The FDA has approved tebentafusp-tebn ( Kimmtrak – Immunocore), a first-in-class bispecific gp100 peptide-HLA-directed CD3 T-cell engager, for treatment of HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults.
Issue 1684 · September 4, 2023 Free
In Brief: Melphalan (Hepzato) for Uveal Melanoma (online only)

The alkylating agent melphalan ( Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects <50% of the liver and no…

Med Lett Drugs Ther. 2023 Sep 4; 65(1684):e148 doi:10.58347/tml.2023.1684d
The alkylating agent melphalan ( Hepzato – Delcath) has been approved by the FDA for treatment of uveal melanoma in adults with unresectable hepatic metastases that affects <50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Melphalan is available in a kit (Hepzato Kit) that contains a hepatic delivery system for infusion into the hepatic artery. The drug has been available for years in a tablet formulation for treatment of multiple myeloma and palliative treatment of nonresectable epithelial ovarian cancer and in an IV solution for treatment of multiple myeloma.